U.S. patent application number 09/764315 was filed with the patent office on 2002-01-17 for method for producing optically active compound.
Invention is credited to Hashimoto, Shin-Ichi, Katsumata, Ryoichi.
Application Number | 20020006645 09/764315 |
Document ID | / |
Family ID | 15507139 |
Filed Date | 2002-01-17 |
United States Patent
Application |
20020006645 |
Kind Code |
A1 |
Hashimoto, Shin-Ichi ; et
al. |
January 17, 2002 |
Method for producing optically active compound
Abstract
The present invention provides a method for industrially
advantageously producing (S)-4-hydroxy-2-ketoglutaric acid and for
producing compounds which are formed by biosynthesis from the
precursor (S)-4-hydroxy-2-ketoglutaric acid, for example, for
producing the compounds (2S,4S)-4-hydroxy-L-glutamic acid and
(2S,4S)-4-hydroxy-L-proli- ne, using a recombinant microorganism
carrying a recombinant DNA harboring the DNA fragment encoding
4(S)-4-hydroxy-2-ketoglutaric acid aldolase gene.
Inventors: |
Hashimoto, Shin-Ichi;
(Tokyo, JP) ; Katsumata, Ryoichi; (Sendai-shi,
JP) |
Correspondence
Address: |
ANTONELLI TERRY STOUT AND KRAUS
SUITE 1800
1300 NORTH SEVENTEENTH STREET
ARLINGTON
VA
22209
|
Family ID: |
15507139 |
Appl. No.: |
09/764315 |
Filed: |
January 19, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09764315 |
Jan 19, 2001 |
|
|
|
09092063 |
Jun 5, 1998 |
|
|
|
6207427 |
|
|
|
|
Current U.S.
Class: |
435/136 ;
435/252.3; 435/252.33 |
Current CPC
Class: |
C12P 7/46 20130101; C12N
9/88 20130101; C12P 13/04 20130101 |
Class at
Publication: |
435/136 ;
435/252.33; 435/252.3 |
International
Class: |
C12P 007/40; C12N
001/21 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 9, 1997 |
JP |
150913/97 |
Claims
What is claimed is:
1. A method for producing an optically active compound, comprising:
(a) allowing a recombinant microorganism carrying a recombinant DNA
harboring (S)-4-hydroxy-2-ketoglutaric acid aldolase gene to act on
sugar and glyoxylic acid in an aqueous medium, and (b) collecting
optically active (S)-4-hydroxy-2-ketoglutaric acid or a compound
from a precursor (S)-4-hydroxy-2-ketoglutaric acid, generated in
the aqueous medium.
2. A method according to claim 1, wherein the compound from the
precursor (S)-4-hydroxy-2-ketoglutaric acid is
(2S,4S)-4-hydroxy-L-glutamic acid.
3. A method according to claim 1, wherein the compound from the
precursor (S)-4-hydroxy-2-ketoglutaric acid is
(2S,4S)-4-hydroxy-L-proline.
4. A method according to any of claims 1-3, wherein the
(S)-4-hydroxy-2-ketoglutaric acid aldolase gene is a gene derived
from microorganisms of genus Escherichia, Pseudomonas, Paracoccus,
Providencia, Rhizobium or Morganella.
5. A method according to any of claims 1-3, wherein the recombinant
microorganism is a microorganism of genus Escherichia or
Corynebacterium.
6. A method according to any of claims 1-3, wherein the recombinant
microorganism is a microorganism having at least one property of
lipoate requirement or reduction or deletion of malic acid synthase
activity.
7. A method according to any of claims 1-3, wherein the recombinant
microorganism is a microorganism with deletion of
phosphoenolpyruvate carboxylase activity.
8. A method according to claim 1 or claim 3, wherein the
recombinant microorganism is a microorganism having resistance to
proline analogs.
9. A method according to claim 1, wherein said compound is selected
from the group consisting of (2S,4S)-4-hydroxy-L-glutamic acid,
(2S,4S)-4-hydroxy-L-proline, (S)-4-hydroxy-L-glutamine,
(S)-4-hydroxy-L-arginine and (S)-4-hydroxy-L-ornithine.
10. A method according to claim 1, wherein the aqueous medium
contains an amino group donor.
11. A method according to claim 1, wherein the aqueous medium does
not contain an amino group donor.
12. A method for producing (2S,4S)-4-hydroxy-L-proline, comprising:
(a) reacting a biocatalyst, having activity to convert
(S)-4-hydroxy-2-ketoglutaric acid into (2S,4S)-4-hydroxy-L-proline,
with (S)-4-hydroxy-2-ketoglutaric acid in an aqueous medium, and
(b) collecting (2S,4S)-4-hydroxy-L-proline generated in the aqueous
medium.
13. A method according to claim 12, wherein the biocatalyst is a
culture or cells or treated products of the microorganisms.
14. A method according to claim 13, wherein the microorganism
belongs to genus Escherichia or Corynebacterium.
15. A method according to claim 13, wherein the microorganism is a
microorganism having resistance to proline analogs.
16. A method according to claim 13, wherein the microorganism is a
microorganism having glutamic acid requirement.
17. Recombinant plasmid pKSR101.
18. A biologically pure culture of Escherichia coli FERM
BP-5919.
19. A biologically pure culture of Escherichia coli FERM
BP-5920.
20. A biologically pure culture of Escherichia coli FERM
BP-5921.
21. A biologically pure culture of Escherichia coli FERM
BP-5922.
22. A biologically pure culture of Escherichia coli FERM
BP-5923.
23. A biologically pure culture of Escherichia coli FERM BP-6382.
Description
BACKGROUND OF THE INVENTION
[0001] Field of the Invention
[0002] The present invention relates to a method for producing
(S)-4-hydroxy-2-ketoglutaric acid and to methods for producing
compounds which can be formed from a precursor
(S)-4-hydroxy-2-ketoglutaric acid, e.g., compounds such as
(2S,4S)-4-hydroxy-L-glutamic acid and (2S,4S)-4-hydroxy-L-proline.
(2S,4S)-4-hydroxy-L-proline has biological activities including
anti-tumor cell activity [Cancer Res. 48., 2483(1988)] and
anti-mast cell activity (Japanese Unexamined Patent Publication No.
63-218621). (S)-4-hydroxy-2-ketoglutaric acid and
(2S,4S)-4-hydroxy-L-glutamic acid are useful for the production of
(2S,4S)-4-hydroxy-L-proline.
[0003] As a conventional method for producing
(S)-4-hydroxy-2-ketoglutaric acid, a number of methods have been
known, including a chemical deamination of
threo-4-hydroxy-L-glutamic acid [Methods in Enzymology, 17 part B,
275].
[0004] The present inventors previously disclosed a method for
producing (S)-4-hydroxy-2-ketoglutaric acid (Japanese Unexamined
Patent Publication No. 7-289284), comprising allowing (e.g.,
providing) a biocatalyst, having activity to generate
(S)-4-hydroxy-2-ketoglutaric acid from pyruvic acid, to act on
glyoxylic acid and pyruvic acid or a compound capable of being
converted into pyruvic acid through the action of the biocatalyst.
Compared with the methods conventionally known, the method is far
more industrially advantageous, but the method is disadvantageous
in that the accumulation of (S)-4-hydroxy-2-ketoglutaric acid is
less if inexpensive glucose is used as the substrate, and that
expensive pyruvic acid should necessarily be used as the substrate
so as to yield an accumulation level of
(S)-4-hydroxy-2-ketoglutaric acid above 20 mM.
[0005] The following conventional methods for producing
(2S,4S)-4-hydroxy-L-glutamic acid have been known; a method
comprising allowing glutamate dehydrogenase to act on chemically
synthesized DL-4-hydroxy-2-ketoglutaric acid in the presence of
ammonia and NADPH and separating the resulting 4(R)- and
4(S)-4-hydroxy-glutamic acid by ion exchange chromatography; a
method comprising extracting (2S,4S)-4-hydroxy-L-glutamic acid from
a plant (Phlox decussata) [Methods in Enzymology, 17 part B, 277];
and a method comprising allowing transaminase to act on
L-4-hydroxy-2-ketoglutaric acid and cysteine sulfinic acid
[Tetrahedron Letters, 28, 1277 (1987)].
[0006] The present inventors have previously disclosed a method for
producing (2S,4S)-4-hydroxy-L-glutamic acid, comprising allowing
(e.g., providing) a biocatalyst, having activity to generate
(2S,4S)-4-hydroxy-L-glutamic acid from pyruvic acid and glyoxylic
acid in the presence of an amino group donor, to act on glyoxylic
acid and pyruvic acid or a compound capable of being converted into
pyruvic acid (Japanese Unexamined Patent Publication No. 8-80198).
The method is industrially advantageous in that only the 4(S) form
can be produced; however, the method is laborious and
disadvantageous in that the method further requires a step of
converting (S)-4-hydroxy-L-ketoglutamic acid into
(2S,4S)-4-hydroxy-L-glutamic acid by adding another bacterium to
(S)-4-hydroxy-L-ketoglutamic acid after the step of synthesis of
(S)-4-hydroxy-L-ketoglutamic acid so as to produce a great amount
of (2S,4S)-4-hydroxy-L-glutamic acid by the method.
[0007] As a conventional method for producing
(2S,4S)-4-hydroxy-L-proline, the following methods have been known;
a method comprising culturing a microorganism of genus Helicoceras
or Acrocylindrium and extracting proline from the culture (Japanese
Unexamined Patent Publication No. 5-111388); and a method
comprising allowing (e.g., providing) a microorganism, having
activity to convert 4-hydroxy-2-ketoglutaric acid into
4-hydroxy-L-proline, to act on 4-hydroxy-2-ketoglutaric acid
(Japanese Unexamined Patent Publication No. 3-266996); and the
like. However, the industrial application of these methods is
difficult, because the yield of the former method is low and the
latter method requires laborious procedures for separation and
purification of the simultaneously generated 4(S) form and 4(R)
form.
SUMMARY OF THE INVENTION
[0008] An object of the present invention is to provide a method
for industrially advantageously producing
(S)-4-hydroxy-2-ketoglutaric acid and compounds produced from the
precursor (S)-4-hydroxy-2-ketoglutamic acid, for example
(2S,4S)-4-hydroxy-L-glutamic acid and
(2S,4S)-4-hydroxy-L-proline.
[0009] The present invention relates to a method for producing an
optically active compound, comprising allowing (e.g., providing) a
recombinant microorganism, carrying recombinant DNA including a DNA
fragment encoding (S)-4-hydroxy-2-ketoglutarate aldolase
(abbreviated as "KAL gene" hereinbelow), to act on sugar and
glyoxylic acid in the presence or absence of an amino group donor
in an aqueous medium and collecting optically active
(S)-4-hydroxy-2-ketoglutaric acid generated in the aqueous medium
or a compound produced from the precursor
(S)-4-hydroxy-2-ketoglutaric acid (abbreviated as "4(S)KHG"
hereinbelow).
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 depicts plasmid pKSR101 and a restriction map of the
plasmid;
[0011] FIG. 2 depicts plasmid pKSR601 and a restriction map of the
plasmid;
[0012] FIG. 3 depicts the construction process of plasmid pKSR125
and a restriction map of the plasmid; and
[0013] FIG. 4 depicts plasmid pKSR50 and a restriction map of the
plasmid.
DETAILED DESCRIPTION OF THE INVENTION
[0014] The present invention relates to a method for producing
(S)-4-hydroxy-2-ketoglutaric acid (4(S)KHG) or to a method for
producing a compound which can be formed from the precursor
4(S)KHG.
[0015] The compound, which can be produced from the precursor
(S)-4-hydroxy-2-ketoglutaric acid, includes
(2S,4S)-4-hydroxy-L-glutamic acid [abbreviated as "4(S)HG"
hereinbelow], (2S,4S)-4-hydroxy-L-proline [abbreviated as "4(S)HYP"
hereinbelow], (S)-4-hydroxy-L-glutamine, (S)-4-hydroxy-L-arigine,
(S)-4-hydroxy-L-ornithine, and the like. (S)-4-hydroxy-L-glutamine,
(S)-4-hydroxy-L-arigine, (S)-4-hydroxy-L-ornithine are useful as a
feed additive for animals.
[0016] According to the present invention, the compound can be
formed directly, using the microorganism carrying the recombinant
DNA harboring the KAL gene (i.e., the precursor 4(S)KHG need not be
formed as an intermediate). Or, the microorganism can be used as a
biocatalyst to convert the precursor 4(S)KHG to the compound. By
referring to the compound from a precursor 4(S)KHG herein, we mean
either technique for forming the compound.
[0017] The method for producing 4(S)KHG, 4(S)HG and 4(S)HYP using a
microorganism carrying a recombinant DNA harboring the KAL gene is
described below.
[0018] The KAL gene includes such gene derived from microorganisms
of genus Escherichia, Pseudomonas, Paracoccus, Providencia,
Rhizobium or Morganella; the KAL gene is preferably the gene from
genus Escherichia. The method for recovering the KAL gene from, for
example, genus Escherichia is now specifically described.
[0019] From a microorganism having activity of
4-hydroxy-2-ketoglutarate aldolase, for example E. coli strain
W3110 (ATCC 14948), the chromosomal DNA is prepared by a
conventional method [Biochim. Biophys. Acta., 72, 619 (1963)].
Based on the nucleotide sequence published in a reference [R. V.
Patil and E. E. Dekker, J. Bacteriol. 174, 102 (1992)], an
oligonucleotide primer is synthesized. Subsequently, polymerase
chain reaction (abbreviated as "PCR" hereinbelow) [R. F. Saiki et
al., Science 230, 1350(1985)] is conducted on a template of the
resulting chromosomal DNA to obtain the above gene.
[0020] To introduce the KAL gene into a host, for example,
Escherichia coli, any vector may be used, including phage vector,
plasmid vector and the like, as long as the vector can be
autonomously replicated or can incorporate the gene into the
chromosome of a host microorganism. Vectors suitable for a
Escherichia coli host include pBR322, pUC119, pACY184 and pTrS33
(Japanese Unexamined Patent Publication No. 2-227075) carrying trp
promoter. A vector suitable for a host of a microorganism of genus
Corynebacteriurn includes a vector from pCG1.
[0021] A recombinant DNA from the KAL gene and a vector DNA can be
prepared together with various recombinant mixtures, by digesting
the two DNAs in vitro with restriction enzymes having the same
restriction site, and subjecting the digested products to ligation
with DNA ligase. Using the resulting recombinant mixture, the host
microorganism is transformed and a transformant strain having
activity to catalyze the reaction to generate 4(S)KHG from pyruvic
acid and glyoxylic acid is selected, whereby the recombinant DNA
can be obtained from the strain. Such recombinant DNA specifically
includes pKSR101, pKSR125 and pKSR601. Transformation can be
carried out according to known methods, for example, molecular
cloning as described in Molecular Cloning, T. Maniatis et al., Cold
Spring Harbor Laboratory, 1982.
[0022] A recombinant microorganism carrying a recombinant DNA
harboring the KAL gene can be prepared, by incorporating a DNA
fragment carrying the genetic information into the vector DNA to
prepare a recombinant DNA, and subsequently transforming a host
microorganism with the resulting recombinant DNA. As such host
microorganism, any microorganism may be usable, as long as the
microorganism can incorporate the recombinant DNA and can express
enzyme activity to catalyze the reaction to generate 4(S)KHG from
pyruvic acid and glyoxylic acid on the basis of the genetic
information. The microorganism may include, for example,
microorganisms of genus Escherichia or Corynebacterium. More
specifically, the microorganism includes for example strain ATCC
33625 of Escherichia coli K-12, Corynebacterium glutamicum
ATCC13032, and Corynebacterium acetoacidophilum FERM P-4962.
[0023] To produce 4(S)KHG, 4(S)HG or 4(S)HYP using the recombinant
microorganism carrying the recombinant DNA harboring the KAL gene,
a microorganism having at least one property of possessing a
lipoate requirement or possessing a reduction or loss of malic acid
synthase activity is preferably used as the host microorganism.
[0024] As such microorganism, any microorganism capable of
incorporating the recombinant DNA and expressing the enzyme
activity to catalyze the reaction to generate 4(S)KHG from pyruvic
acid and glyoxylic acid on the basis of the genetic information may
be used, including for example microorganisms of genus Escherichia
or Corynebacterium. More specifically, the microorganism includes
for example strain ATCC 33625 of Escherichia coli K-12,
Corynebacterium glutamicum ATCC 13032, and Corynebacterium
acetoacidophilum FERM P-4962.
[0025] More specifically, an Escherichia coli K-12 sub-strain NHK40
[lipoate requirement (lip), 4KAL deletion (eda)] may be used. The
strain NHK40 was deposited with the National Institute of
Bioscience and Human-Technology, Agency of Industrial Science and
Technology in Japan on Apr. 16, 1997 as FERM BP-5919 under the
Budapest Treaty.
[0026] To produce 4(S)HG, a microorganism in which
phosphoenolpyruvate carboxylase activity is deleted is preferably
used as the host microorganism.
[0027] As such microorganism, any microorganism capable of
incorporating the recombinant DNA and expressing the enzyme
activity to catalyze the reaction to generate 4(S)KHG from pyruvic
acid and glyoxylic acid on the basis of the genetic information may
be used, including for example microorganisms of genus Escherichia
or Corynebacterium. More specifically, the microorganism includes,
for example, strain ATCC 33625 of Escherichia coli K-12,
Corynebacterium glutamicum strain ATCC 13032, and Corynebacterium
acetoacidophilum FERM P-4962.
[0028] More specifically, an Escherichia coli K-12 sub-strain NHK46
[lip, eda, malic acid synthase deletion (glc), phosphoenolpyruvate
carboxylate deletion (ppc)] may be used. The Escherichia Coli NHK46
was deposited with the National Institute of Bioscience and
Human-Technology, Agency of Industrial Science and Technology in
Japan on Apr. 16, 1997 as FERM BP-5920 under the Budapest
Treaty.
[0029] To produce 4(S)HYP, alternatively, a microorganism having at
least one property of a lipoate requirement, the reduction or
deletion of malic acid synthase activity and deletion of
phosphoenolpyruvate carboxylase activity and being resistant to
proline analogs is more preferably used. Such proline analogs
include azetidine-2-carboxylic acid, 3,4-dehydroproline and
thioproline.
[0030] As such microorganism, any microorganism capable of
incorporating the recombinant DNA and expressing the enzyme
activity to catalyze the reaction to generate 4(S)KHG from pyruvic
acid and glyoxylic acid on the basis of the genetic information may
be used, including for example microorganisms of genus Escherichia
or Corynebacterium. More specifically, the microorganism includes
strain ATCC 33625 of Escherichia coli K-12, Corynebacterium
glutamicum strain ATCC 13032, and Corynebacterium acetoacidophilum
FERM P-4962.
[0031] More specifically, an Escherichia coli K-12 sub-strain NHK47
[having lip, eda, glc, ppc, and anti-azetidine-2-carboxylate
resistance] is mentioned. The Escherichia coli strain NHK47 was
deposited with the National Institute of Bioscience and
Human-Technology, Agency of Industrial Science and Technology in
Japan on Apr. 16, 1997 as FERM BP-5921 under the Budapest
Treaty.
[0032] The various deletion strains or resistant strains mentioned
above may be strains of wild type having the properties described
above, or may be obtained by subjecting their parent strains with
no such properties to conventional mutation process such as
treatment with mutation agents for example
N-methyl-N'-nitro-N-nitrosoguanidine (NTG), UV irradiation or
.gamma. irradiation, coating the resulting strains on an
appropriate agar plate medium, harvesting a grown mutant strain,
and selecting a strain with the deletion or reduction of the
objective enzyme activity compared with the parent strains or
harvesting a strain more resistant to the analogs than the parent
strains. Transducing the deletion mutation (transduction) from a
strain with the objective deletion or resistance mutation into a
desirable strain, using phage Pi, allows recovery of various
deletion mutant strains and resistance mutant strains for strains
of the Escherichia coli K-12 [J. H. Miller, Experiments in
Molecular Genetics, Cold Spring Harbor Laboratory (1972)].
[0033] The microorganism to be used in accordance with the present
invention can be cultured by conventional culturing procedures. The
culture medium to be used for such culturing may be any natural
medium or any synthetic medium, as long as the medium contains
carbon source, nitrogen source, inorganic salts and the like, which
can be assimilated by the microorganism to be used, whereby the
microorganism can be cultured efficiently. Any carbon source which
can be assimilated by the microorganism to be used may be usable,
including sugars such as glucose, fructose, sucrose, maltose,
starch, starch hydrolysate, and molasses; organic acids such as
acetic acid, lactic acid and gluconic acid; or alcohols such as
ethanol and propanol. Any nitrogen source which can be assimilated
by the microorganism may be usable, including inorganic salts such
as ammonia, ammonium sulfate, ammonium chloride, and ammonium
phosphate; ammonium salts of organic acids, peptone, casein
hydrolysate, meat extract, yeast extract, corn steep liquor, soy
bean bran, soy bean bran hydrolysate, various fermentation bacteria
and digestion products of the bacteria. Any inorganic salt which
can be assimilated by the microorganism may be usable, including
potassium phosphate, ammonium sulfate, ammonium chloride, sodium
chloride, magnesium sulfate, ferrous sulfate and manganese sulfate.
Additionally, salts of calcium, zinc, boron, copper, cobalt and
molybdenum may be added as trace elements. If necessary, the
culture medium may contain vitamins such as for example thiamin and
biotin, amino acids such as glutamic acid and aspartic acid, and
nucleic acid-related substances such as adenine and guanine.
Culturing is carried out under aerobic conditions, by agitation
culture or submerged aeration agitation culture. The culturing is
carried out at preferably 20 to 45.degree. C. for 10 to 96 hours at
pH 5.0 to 9.0. The pH is adjusted with inorganic or organic acids,
alkaline solutions, urea, calcium carbonate, and ammonia. The
culture thus produced may be used as it is for the objective
reaction; in the alternative, the culture may be treated, and the
resulting treated product may be subjected to the subsequent
reaction. The treated product includes the forms of condensate and
dried product, freeze-dried product, surfactant-treated product,
organic solvent-treated product, thermally treated product,
enzymatically treated product, ultrasonication-treated product and
mechanical disruption-treated product of the culture, and
immobilized products of the bacteria or treated products of the
bacteria.
[0034] Examples of the aqueous medium to be used in the present
invention include water; buffers such as phosphate, carbonate,
acetate, borate, citrate, and Tris; and aqueous solutions
containing organic solvents including alcohols such as methanol and
ethanol; esters such as ethyl acetate; ketones such as acetone; and
amides such as acetamide. If necessary, furthermore, surfactants
such as Triton X-100 (Nacalai Tesque, Inc.) and Nonion HS204 (NOF
Corporation), as well as organic solvents such as toluene and
xylene, may be added at about 0.1 to 20 g/liter into the
medium.
[0035] The amino group donor to be used in accordance with the
present invention includes ammonia; inorganic ammonium salts such
as ammonium sulfate, ammonium chloride, and urea; and various amino
acids such as glutamic acid. The concentration of the amino group
donor is 0.1 to 100 g/liter, preferably 1 to 50 g/liter.
[0036] The concentration for production of 4(S)KHG by allowing the
recombinant microorganism carrying the recombinant DNA harboring
the KAL gene to act on sugar and glyoxylic acid, is generally 5 to
100 g/liter. The concentrations of sugar and glyoxylic acid are
both 1 to 200 g/liter, preferably 20 to 200 g/liter. Any sugar
which can be assimilated by the recombinant strain may be usable,
including glucose, fructose, sucrose, maltose, starch, starch
hydrolysate and molasses The reaction is carried out at 15 to
80.degree. C., preferably 25 to 60.degree. C., at a pH of 3 to 11,
preferably a pH of 5 to 9, for 1 to 96 hours.
[0037] In the above process, 4(S)KHG may be prepared by adding
glyoxylic acid at the concentration mentioned above, at the
starting point or in the course of the culturing of a microorganism
carrying the recombinant DNA harboring the KAL gene. Sugar may be
added in advance as the culture substrate or may be added together
with glyoxylic acid.
[0038] The resulting 4(S)KHG may be isolated and purified by
conventional purification processes of organic acids. From the
reaction supernatant from which solids are removed by centrifuge,
for example, 4(S)KHG can be isolated and purified by a process by
means of ion exchange resin and membrane process in
combination.
[0039] As the sugar used for producing 4(S) HG or 4(S) HYP by
allowing the recombinant microorganism carrying the recombinant DNA
harboring the KAL gene to act on sugar and glyoxylic acid in an
aqueous medium in the presence of an amino group donor, any sugar
which can be assimilated by the recombinant strain may be used,
including glucose, fructose, sucrose, maltose, starch, starch
hydrolysate, and molasses. The bacterial concentration for the
reaction is generally 5 to 100 g/l. The concentrations of sugar and
glyoxylic acid are both 1 to 200 g/l, preferably 10 to 200 g/l. The
reaction is carried out at 15 to 80.degree. C., preferably 25 to
60.degree. C. at a pH of 3 to 11, preferably a pH of 5 to 9, for 1
to 96 hours. In the process, 4(S)HG or 4(S)HYP may be prepared by
adding glyoxylic acid at the concentration mentioned above at the
starting point of or in the course of the culturing of a
microorganism carrying the recombinant DNA harboring the KAL
gene.
[0040] Additionally, 4(S)HYP may also be produced by adding a
biocatalyst having activity to convert 4(S)KHG into 4(S)HYP, with 4
(S) KHG in the presence of an amino group donor to an aqueous
medium.
[0041] An example of the use of 4(S)KHG for producing 4(S)HYP
include isolated and purified 4(S)KHG, a crude sample thereof which
contains no 4(R)KHG or 4(R)HG therein, and a reaction solution
containing 4(S)KHG formed through the reaction of a biocatalyst.
The concentration of 4 (S)KHG is 1 to 200 g/liter, preferably 20 to
200 g/liter.
[0042] Examples of the biocatalyst having activity of converting
4(S)KHG into 4(S)HYP in the presence of the amino group donor
include cells, a culture and processed cells of microorganisms
having activity of converting 4(S)KHG into 4(S)HYP. Such
microorganisms include microorganisms of genus Escherichia and
Corynebacterium. More specifically, the microorganisms include
strain ATCC 33625 of Escherichia coli K-12, which is prepared by
modifying proBA gene (encoding proB and proA) coding for the enzyme
of proline synthesis in Escherichia coli and then preparing plasmid
pKSR25 carrying the resulting mutant proBA gene with reduced feed
back inhibition, and thereafter introducing the plasmid into an
Escherichia coli strain. More preferably, a mutant strain with a
glutamic acid requirement is mentioned. Such a mutant strain can be
prepared by subjecting its parent strain to conventional
mutagenesis technique, for example,
N-methyl-N'-nitro-N-nitrosoguanidine (NTG), UV irradiation or
.gamma. irradiation, coating the resulting strains on an
appropriate agar plate medium, harvesting a grown mutant strain,
and selecting a strain with glutamic acid requirement for the
growth. In a case of a microorganism of Escherichia coli K-12,
furthermore, a deletion mutant strain can also be produced by
transduction. Such a microorganism includes NHK3/pKSR25 strain,
which is prepared by first obtaining an isocitrate dehydrogenase
deletion mutation (icd) of strain ATCC 33625 of Escherichia coli
K-12 to obtain strain NHK3, and subsequently introducing pKSR25
into strain NHK3; such a microorganism also includes strain
(NHK3/pKSR25+pKSR50), with plasmid pKSR50 additionally containing
glutamate dehydrogenase and glucose-6-phosphate dehydrogenase
having been introduced therein. A host microorganism with a
glutamic acid requirement and with resistance to
azetidine-2-carboxylic acid and proline analogs such as
3,4-dehydroproline and thioproline is more advantageously used.
Such microorganism can be obtained by subjecting its parent strain
to mutagenesis and transduction; additionally, the microorganism
can be obtained by introducing a plasmid having proline analog
resistance into the parent strain. More specifically, Escherichia
coli strain NHK23/pKSR25+pKSR50 is mentioned. Escherichia coli
strains NHK3/pKSR25+pKSR50 and Escherichia coli strain
NHK23/pKSR25+pKSR50 were deposited with the National Institute of
Bioscience and Human-Technology, Agency of Industrial Science and
Technology in Japan on Apr. 16, 1997 as FERM BP-5922 and BP-5923,
respectively, under the Budapest Treaty.
[0043] The concentration of the biocatalyst to be used for the
reaction is generally 5 to 100 g/liter. The reaction is carried out
at 15 to 80.degree. C., preferably 25 to 60.degree. C. at a pH of 3
to 11, preferably a pH of 5 to 9, for 1 to 96 hours. 4 (S)HYP is
produced by adding 4(S)KHG at the starting point of or in the
course of culturing of a microorganism having activity of
converting 4(S)KHG into 4(S)HYP in the presence of the amino group
donor.
[0044] 4(S)HG or 4(S)HYP thus produced can be isolated by
conventional purification methods for amino acids. By a combination
of an ion exchange resin and a membrane process, for example,
4(S)HG or 4(S)HYP can be isolated from a reaction supernatant from
which solids are preliminarily removed by centrifugation.
EXAMPLES
[0045] The present invention will now be described in more detail
in the following examples. Unless otherwise specified, the general
procedures for recombinant DNA were according to the method
described in Molecular Cloning, A Laboratory Manual, T. Maniatis et
al., Cold Spring Harbor Laboratory, 1982.
Example 1
[0046] Preparation of Plasmid Containing KAL Gene
[0047] One platinum loop of strain W 3110 (ATCC 14948) of
Escherichia coli K-12 was inoculated in a 10-ml LB liquid medium
[containing Bactotrypton (10 g; manufactured by Difco, Co.), yeast
extract (5 g; manufactured by Difco, Co.) and NaCl (5 g) per one
liter of water and having been adjusted to pH 7.2], for culturing
at 30.degree. C. for 20 hours. From the cultured microorganisms was
isolated chromosomal DNA by a known method [H. Saito & K. I.
Miura, Biochim. Biophys. Acta., 72, 619(1963)].
[0048] Based on the nucleotide sequence of the KAL gene as reported
[R. V. Patil and E. E. Dekker, J. Bacteriol. 174, 102(1992)], an
oligonucleotide of the DNA sequence of Sequence No.1 corresponding
to the N terminus of the genetic product and an oligonucleotide of
the DNA sequence of Sequence No.2 corresponding to the C terminus
of the KAL gene were individually synthesized by conventional
methods. Using these oligonucleotides as the primers, the KAL gene
was amplified by PCR [R. F. Saiki, et al., Science 230, 1350
(1985)]. Using the isolated chromosomal DNA of the Escherichia coli
W 3110 (ATCC 14948) as the template, amplification was conducted
with Gene Amp.TM. kit (manufactured by Perkin Elmer, Japan) and a
DNA thermal cycler manufactured by the same Company, for 30 cycles
of each cycle composed of 94.degree. C. for 30 seconds, 52.degree.
C., for 30 seconds and 72.degree. C. for one minute, followed by
reaction at 72.degree. C. for 5 minutes. After the termination of
the reaction, the amplified DNA fragment of about 630 bps was
extracted with chloroform and purified through ethanol
precipitation. The DNA fragment (2 .mu.g) and vector plasmid pTrS33
(1 .mu.g) (Japanese Unexamined Patent Publication No. 2-227075)
carrying the trp promoter were independently digested with HindIII
and BamHI in a double fashion, and were then purified by agarose
gel electrophoresis. The purified two fragments were mixed
together, prior to ethanol precipitation, and the resulting mixture
was then dissolved in distilled water (5 .mu.l) and subjected to
ligation, to prepare recombinant DNA.
[0049] The recombinant DNA obtained was used to transform the
Escherichia coli ATCC 33625 using the method of Maniatis et al.
[Molecular Cloning, A Laboratory Manual, Cold Spring Harbor
Laboratory (1982)], and the resulting strains were then smeared on
an LB agar culture medium containing 100 .mu.g/ml ampicillin, and
incubated at 37.degree. C. for 24 hours. The resulting eight
ampicillin-resistant transformant colonies were assayed for
activity to synthesize 4-hydroxy-2-ketoglutaric acid from pyruvic
acid and glyoxylic acid. More specifically, each transformant
strain was cultured in an LB liquid medium (3 ml) containing 100
.mu.g/ml ampicillin at 30.degree. C. for 20 hours, followed by
addition of xylene (30 .mu.l), 2M sodium pyruvate (150 .mu.l) and
2M glyoxylic acid solution (150 .mu.l; adjusted to pH 6.4 by using
NaOH) to the culture solution, with shaking at 37.degree. C. for 30
minutes. The supernatant from the centrifuged reaction solution was
assayed by high-performance liquid chromatography (HPLC), to
measure the yield of 4(R)- and 4(S)-4-hydroxy-2-ketoglutaric
acids.
[0050] HPLC Assay Conditions
[0051] Column; SUMICHIRAL OA-5000 column, manufactured by Sumitomo
Chemical Assay Center, Co.
[0052] Mobile phase; a mixture solution of a pair of 1 mM copper
(II) sulfate and aqueous 0.1 mM ammonium acetate solution (pH 4.5)
and isopropanol at 85:15, in this order.
[0053] Flow rate; 1 ml/min
[0054] Temperature; 40.degree. C.
[0055] Detection; absorbance at UV 210 nm.
[0056] As a result, the ability to actively synthesize 4(S)KHG was
observed in any of the transformants. Additionally, these strains
were cultured with agitation in an LB liquid medium (3 ml)
containing 100 .mu.g/ml ampicillin at 37.degree. C. for 16 hours
prior to centrifugation, and plasmids were isolated from the
resulting microorganisms according to the known method [Molecular
Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory
(1982)], and digested with various restriction enzymes to determine
the structures. It was observed that all these plasmids had the
same structure. The plasmid thus prepared was defined as pKSR101.
The restriction map of pKSR101 is shown in FIG. 1. With respect to
pKSR101, the Escherichia coli NHK46/pKSR101, which carries pKSR101,
was deposited with the National Institute of Bioscience and
Human-Technology, Agency of Industrial Science and Technology in
Japan on Jun. 2, 1998 as FERM BP-6382 under the Budapest
Treaty.
[0057] To introduce 4(S)KAL gene into a microorganism of genus
Corynebacterium, the pKSR 101 was ligated to a vector plasmid
pCS116 (Japanese Unexamined Patent Publication No. 6-277082)
autonomously replicable. pCS 116 (1 .mu.g) and pKSR11 (1 .mu.g)
were dissolved in H buffer (45 .mu.l; manufactured by Takara
Brewery), to which was added 10 units of Bgl II for digestion At
37.degree. C. for 3 hours, followed by phenol extraction and
ethanol precipitation. The resulting matter was dissolved in
distilled water (5 .mu.l) for ligation, to prepare a recombinant
DNA. Using the recombinant DNA, the Escherichia Coli ATCC33625 was
transformed by the method of Maniatis et al. [Molecular Cloning, A
Laboratory Manual, Cold Spring Harbor Laboratory (1982)]. The
resulting strains were smeared on an LB agar culture medium
containing 100 .mu.g/ml ampicillin and 100 .mu.g/ml spectinomycin
and incubated at 37.degree. C. for 24 hours. From the resulting
colonies resistant to ampicillin and spectinomycin, plasmids were
isolated in the same manner as described above, and Corynebacterium
glutamicum ATCC 13032 was transformed with the plasmid by the known
method (Japanese Unexamined Patent Publication No. 6-277082). The
transformant was then smeared on a BY agar culture medium
containing 100 .mu.g/ml glutamicum [the medium contained bouillon
(20 g; manufactured by Kyokuto Co.) and yeast extract (5 g;
manufactured by Kyokuto Co.) in water of one liter and having been
preliminarily adjusted to pH 7.2 and solidified through the
addition of 2% agar], and incubated at 30.degree. C. for 48 hours.
By the known method (Japanese Unexamined Patent Publication No.
57-183799), plasmids were isolated from the eight resulting
spectinomycin-resistant colonies to determine the structure. As a
result, it was observed that all these plasmids had the same
structure. The plasmid thus prepared was defined as pKSR601. The
restriction map of pKSR601 is shown in FIG. 2.
Example 2
[0058] Preparation of 4(S)KHG in Mutant Strain of Escherichia
coli
[0059] A ppc Mutation was given to a strain WA802 of Escherichia
coli K-12 [J. Mol. Biol. 16, 118 (1966)], through transduction
using P1 phage from a strain DV21A05 with ppc mutation of
Escherichia coli K-12 strain [J. Bacterial. 132, 832(1977)], and by
further using the transduction process by means of the P1 phage, a
lip mutation was given and an eda mutation was subsequently given
to the strain, to prepare a strain NHK42 with mutation of ppc, lip
and eda triple deletions. From the strain NHK 42, a strain with
reduced malic acid synthase activity was induced. The
microorganisms of the strain NHK42 cultured up to the logarithmic
growth stage in an LB medium containing 2 g/l glutamic acid and 100
.mu.g/l lipoic acid, were centrifuged and harvested, rinsed in
0.05M Tris-maleate buffer solution (pH 6.0), and suspended in the
buffer solution to a final bacterial concentration of 10.sup.9
cells/ml. NTG was added into the suspension to a final
concentration of 600 mg/l, and the resulting mixture was retained
at ambient temperature for 20 minutes for mutagenesis. After the
mutagenesis, the microorganisms were smeared on an M9 minimal agar
culture medium with addition of 0.5% glucose, 0.05 g/l glutamic
acid, 100 .mu.g/l lipoic acid, and 30 mM glyoxylic acid [Molecular
Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1982)
]. After 2-day incubation at 37.degree. C., small colonies among
the generated colonies were collected in an LB agar culture medium
with addition of 2 g/l glutamic acid and 100 .mu.g/l lipoic acid.
The collected mutant strains were replicated in an M9 minimal agar
culture medium with addition of 0.5% glucose, 0.5 g/l glutamic acid
and 100 .mu.g/l lipoic acid, and in an M9 minimal agar culture
medium with addition of 0.5% glucose, 100 .mu.g/l lipoic acid, and
30 mM glyoxylic acid. Then, strains growing in the former medium
but never growing in the latter medium were selected. The selected
strains were cultured with agitation in an MS medium [the medium
contained 3 g glucose, 4 g KH.sub.2PO.sub.4, 10 g (NH.sub.4)
2SO.sub.4, 1 g MgSO.sub.4, 100 .mu.g thiamin hydrochloride, 1 g
yeast extract, 1 g peptone, 50 .mu.g lipoic acid, 20 g CaCO.sub.3,
and 2 g glutamic acid per one liter of water and had been adjusted
to pH 7.2] at 37.degree. C. At the later stage of the logarithmic
growth, the microorganisms were harvested and rinsed in 50 mM
Tris-hydrochloric acid buffer (pH 7.0), and the microorganisms were
then disrupted with an ultrasonication disrupting machine and
centrifuged at 15,000 rpm for 45 minutes, to obtain the
supernatant, which was defined as cell extract solution. Using the
cell extract solution, the malic acid synthase activity was assayed
by a known reference [Methods in Enzymology 5, 633 (1962)]. A
strain NHK46 which was detected to have no activity was selected as
the objective mutant strain.
[0060] Using the transduction process employing a P1 phage, the
lip.sup.+ gene was introduced from the Escherichia coli W 3110
(ATCC 14948) into the strain NHK 46, to prepare strain NHK 48 with
no requirement of lipoic acid.
[0061] Using the method of Maniatis et al. [Molecular Cloning, A
Laboratory Manual, Cold Spring Harbor Laboratory (1982) ], pKSR101
was introduced into strains NHK 42, NHK 46 and NHK 48 (provided
that culturing was conducted after 100 .mu.g/l lipoic acid and 2
g/l glutamic acid were added to the medium), to obtain
transformants using as the marker for ampicillin resistance.
[0062] Each transformant was cultured with agitation in an LB
medium containing 1% glucose, 2% calcium carbonate, 100 .mu.g/l
lipoic acid, and 2 g/l glutamic acid at 28.degree. C. for 16 hours.
Each culture broth was added into a sterilized T medium of 5 ml
[the medium contained 50 g glucose, 4 g KH.sub.2PO.sub.4, 10 g
(NH.sub.4) 2SO.sub.4, 1 g MgSO.sub.4, 10 .mu.g thiamin
hydrochloride, 0.2 g yeast extract, 3 g KCl, 50 .mu.g lipoic acid,
250 mg tryptophan, 20 g CaCO.sub.3, and 2 g glutamic acid per one
liter of water and had been adjusted to pH 7.2], at 30.degree. C.
for 24 hours, followed by addition of 0.25 ml of 2M glyoxylic acid
solution (adjusted to pH 6.4 by using NaOH), prior to another
24-hour agitation culture at 37.degree. C. The obtained culture
broth was centrifuged, and the resulting culture supernatant was
analyzed by HPLC to assay the yields of 4(R)KHG and 4(S)KHG. The
results are shown in Table 1. As apparently shown in the yields of
4(S)KHG, the mutation for lipoate requirement and mutation for
reduction of malic acid synthase activity make a contribution to
the yield of 4(S)KHG.
1TABLE 1 Host Plasmid 4(R)KHG(mM) 4(S)KHG(mM) Escherichia coli
pKSR101 0.8 7.5 NHK42 Escherichia coli pKSR101 3.1 28.1 NHK46
Escherichia coli pKSR101 0.0 0.0 NHK48
Example 3
[0063] Production of 4(S)KHG in Corynebacterium glutamicum
[0064] Corynebacterium glutamicum strain ATCC 13032 introduced with
pKSR601 was cultured with agitation in an LB culture medium for 16
hours. The culture broth (0.5 ml) was added into a sterilized TC
medium (5 ml) [the medium contained 10 g glucose, 0.5 g
KH.sub.2PO.sub.4, 0.5 g K.sub.2HPO.sub.4, 20 g
(NH.sub.4).sub.2SO.sub.4, 0.25 g MgSO.sub.4, 3 g urea, 100 .mu.g
biotin, 5 g corn steep liquor, 10 mg FeSO.sub.4.7aq, 5 mg
MnSO.sub.4.4-6aq, and 20 g CaCO.sub.3 per one liter of water and
had been adjusted to pH 7.2], and cultured with agitation at
30.degree. C. for 24 hours. Then, 2M glyoxylic acid solution (0.25
ml; adjusted to pH 6.4 by using NaOH) was added thereto and the
mixture was cultured with agitation at 37.degree. C. for further 24
hours. The culture supernatant was analyzed by HPLC in the same
manner as in Example 2. The yield of 4(S)KHG was 34.7 mM with no
generation of 4(R)KHG.
Example 4
[0065] Scale Up Production of 4(S)KHG
[0066] On the basis of the results in Example 2, pKSR11 was
introduced into the strain NHK40 with double deletion mutation of
lip and eda among the strains of Escherichia coli K-12 as in
Example 2, to prepare a strain to generate 4(S)KHG. The
transformant was cultured with agitation in an LB medium containing
1% glucose, 2% calcium carbonate and 100 .mu.g/l lipoic acid at
28.degree. C. for 13 hours. The culture broth (10 ml) was added to
the same culture medium of 200 ml in a 1-liter sterilized
Erlenmeyer flask and cultured with agitation at 28.degree. C. for
13 hours. The total volume of the culture broth was added to the J1
culture medium of the composition shown in Table 2 in a 5-liter
sterilized jar, and cultured at an aeration of 2 liter/min and
agitation of 500 rpm and 33.degree. C., while the pH of the medium
was kept at pH 6.8 by using aqueous ammonia. Twenty hours later,
xylene (20 ml) and 2M glyoxylic acid solution (adjusted to pH 6.4
by using NaOH) were added into the jar, and further cultured at
37.degree. C. for 12 hours. The culture supernatant was analyzed by
HPLC, and it was observed that the yield of 4(S)KHG was 305 mM.
2TABLE 2 Composition of J1 culture medium (per one liter; adjusted
to pH 6.8) Glucose 30 g KH.sub.2PO.sub.4 2 g K.sub.2HPO.sub.4 2 g
(NH.sub.4).sub.2SO.sub.4 10 g MgSO.sub.4 1 g FeSO.sub.4.7aq 10 mg
MnSO.sub.4.4-6aq 10 mg CoCl.sub.2 1.5 mg CaCl.sub.2 15 mg
NiCl.sub.2 1.5 mg Ammonium molybdate 1.5 mg Thiamin hydrochloride
salt 100 .mu.g Yeast extract 0.5 g KCl 3 g Lipoic acid 75 .mu.g
Tryptophan 250 mg
Example 5
[0067] Production of 4(S)KHG in Various Strains
[0068] Using a transduction process employing a P1 phage [J. H.
Miller, Experiments in Molecular Genetics, Cold Spring Harbor
Lab.(1972)], ppc+ gene was introduced from the Escherichia coli
W3110 (ATCC 14948) into the strain NHK42, to prepare strain NHK45
with no requirement of glutamic acid. pKSR101 was introduced into
the strain in the same manner as in Example 2.
[0069] The strains NHK 42, 46, 48 and 45, all of which are
introduced with pKSR101, were cultured in the same manner as in
Example 2, and the resulting culture supernatants were assayed by
HPLC to measure the yields of 4(R)HG and 4(S)HG.
[0070] HPLC Assay Conditions
[0071] Column; Lichrospher (C18) column, manufactured by Merck, Co.
Mobile phase; solution containing 10 mM sodium citrate, 10 mM
anhydrous sodium sulfate (pH 2.2), 0.4% n-propanol, and 0.03%
SDS.
[0072] Flow rate; 0.8 ml/min
[0073] Temperature; 40.degree. C.
[0074] Detection; detected after the eluted solution was treated
with o-phthalic aldehyde by post column labeling.
[0075] Ex=350 nm, Em=448 nm.
[0076] The results are shown in Table 3. As is apparent from the
yields of 4(S)HG of each strain, a mutation for lipoate
requirement, a mutation for reduced malic acid synthetase activity,
and a mutation for deletion of phosphoenolpyruvate carboxylase can
make a contribution to the production of 4 (S)HG.
[0077] Corynebacterium glutamicum ATCC 13032 introduced with
pKSR601 was cultured with agitation in an LB culture medium for 16
hours. The culture broth (0.5 ml) was added into a sterilized TC
medium (5 ml) [the medium contained 100 g glucose, 0.5 g
KH.sub.2PO.sub.4, 0.5 g K.sub.2HPO.sub.4, 20 g
(NH.sub.4).sub.2SO.sub.4, 0.25 g MgSO.sub.4, 3 g urea, 100 .mu.g
biotin, 5 g corn steep liquor, 10 mg FeSO.sub.4.7aq, 5 mg
MnSO.sub.4.4-6aq, and 20 g CaCO.sub.3 per one liter of water and
had been adjusted to pH 7.2], and cultured with agitation at
30.degree. C. for 24 hours. Then, 2M glyoxylic acid solution (0.25
ml; adjusted to pH 6.4 by using NaOH) was added, and the mixture
was further cultured at 37.degree. C. for 24 hours. The culture
supernatant was analyzed by HPLC in the same manner as described
above to assay the yields of 4(R)HG and 4(S)HG.
[0078] The results are shown in Table 3.
3TABLE 3 Host Plasmid 4(R)HG(mM) 4(S)HG(mM) Escherichia coli
pKSR101 0.1 14.0 NHK42 Escherichia coli pKSR101 0.1 21.9 NHK46
Escherichia coli pKSR101 0.0 1.5 NHK48 Escherichia coli pKSR101 0.1
3.7 NHK45 Corynebacterium pKSR601 0.0 9.8 glutamicum ATCC13032
Example 6
[0079] Scale Up Production of 4(S)HG
[0080] Escherichia Coli strain NHK 46 introduced with pKSR101 was
cultured with agitation in an LB culture medium containing 1%
glucose, 2% calcium carbonate, 100 .mu.g/l lipoic acid, and 2 g/l
glutamic acid at 28.degree. C. for 13 hours. The culture broth (10
ml) was added to the same culture medium of 200 ml in a 1-liter
sterilized Erlenmeyer flask and cultured with agitation at
28.degree. C. for 13 hours. The total volume of the culture broth
was added to the J2 culture medium of the composition shown in
Table 4 in a 5-liter sterilized jar, and cultured at an aeration
volume of 2 liter/min and agitation of 500 rpm and 33.degree. C.,
while the pH of the medium was kept at pH 6.8 by using aqueous
ammonia. Fourteen hours later, 2M glyoxylic acid solution (350 ml;
adjusted to pH 6.4 by using NaOH) was added into the jar, and
further cultured at 37.degree. C. for 60 hours while appropriately
adding glucose. The culture supernatant was analyzed by HPLC in the
same manner as in Example 5, and it was observed that the yield of
4(S)HG was 141.7 mM and the yield of 4(R)HG was 6 mM.
4TABLE 4 Composition of J2 culture medium (per one liter; adjusted
to pH 6.8) Glucose 30 g KH.sub.2PO.sub.4 2 g K.sub.2HPO.sub.4 2 g
(NH.sub.4).sub.2SO.sub.4 10 g MgSO.sub.4 1 g FeSO.sub.4.7aq 10 mg
MnSO.sub.4.4-6aq 10 mg CoCl.sub.2 1.5 mg CaCl.sub.2 15 mg
NiCl.sub.2 1.5 mg Ammonium molybdenate 1.5 mg Thiamin hydrochloride
salt 100 .mu.g Yeast extract 0.5 g KCl 3 g Lipoic acid 75 .mu.g
Tryptophan 250 mg Glutamic acid 12 g Isoleucine 20 mg Methionine 10
mg
Example 7
[0081] Purification of 4(S)HG
[0082] Employing centrifugation, microorganisms were removed from
the culture broth (one liter) containing 4(S)HG and 4(R)HG as
obtained in Example 6, and the resulting culture supernatant was
passed through a column packed with a cation exchange resin SK1B
(500 ml) (H.sup.+ type, manufactured by Mitsubishi Chemical
Corporation). After rinsing with water, aqueous 1N ammonia was
passed through the column to fractionate an HG eluate fraction. The
fractionated solution was subjected to a decoloring process on
active charcoal, and half of the resulting solution was passed
through a column packed with an anion exchange resin PA316 (400 ml)
(OH type, manufactured by Mitsubishi Chemical Corporation). After
rinsing with water, 0.5N hydrochloric acid was passed through the
column to fractionate an HG eluate fraction. By evaporation,
hydrochloric acid was removed from the fractionated solution, and
the resulting solution was concentrated to 50 ml, which was then
left to stand at 4.degree. C. for 2 days. The crystal generated in
the liquid was filtered to recover 4(S)HG (7 g). By NMR analysis,
mass spectrometry and optical rotation assay, the crystal was
confirmed to be 4(S)HG with no 4(R)HG present. Therefore, using
strain NHK46, 4(S)HG can be collected in a one-step reaction with
no contamination from 4(R)HG.
Example 8
[0083] Ligation of Proline Synthase Gene to KAL Gene
[0084] Firstly, A mutant proBA gene desensitized against the
proline feedback inhibition was prepared by modifying proBA
(encoding proB and proA) gene coding for the proline bio-synthase
in the following manner.
[0085] Escherichia coli-derived plasmid pPRO-1 (Japanese Unexamined
Patent Publication No. 3-266995) containing the proBA gene was
digested with EcoRV, and the digested products were then
electrophoresed on agarose gel to isolate and purify a DNA fragment
containing a part of the proB gene using prep-A-Gene DNA
Purification System (manufactured by Bio-Rad Co.). The fragment was
ligated to a digested product obtained by digesting pUS119
(manufactured by Takara Brewery, Co.) with SmaI. The resulting
ligation product was used to transform Escherichia coli ATCC 33625
to prepare ampicillin resistant transformants. A plasmid was
extracted from one of these transformants by conventional methods
for restriction analysis. It was confirmed that the plasmid was
inserted with a DNA fragment of about 1 kb containing a part of the
proB gene at the SmaI site of pUC119. The plasmid was defined as
pBAB51.
[0086] On the basis of the nucleotide sequence of the known
desensitized proB enzyme gene (proB74 mutation) [A. M. Dandekar and
S. L. Uratsu, J. Bacteriol. 170, 5943(1988)], an oligonucleotide A1
of the sequence of Sequence No.3 and an oligonucleotide A2 of the
sequence of Sequence No.4 were synthetically prepared by
conventional methods. By subsequently using a pair of the
oligonucleotide A1 and M13 primer M3 (manufactured by Takara
Brewery, Co.) as a primer and also using a pair of the
oligonucleotide A2 and M13 primer RV (manufactured by Takara
Brewery, Co.) as another primer, independently, a partial sequence
of the mutant proB gene was amplified by PCR using pBAB51 as the
template, in the same manner as in Example 1. The amplified DNA was
electrophoresed on agarose gel and purified using a Prep-A-Gene DNA
Purification System (Bio-Rad, CO.). Using a mixture of these two
DNA fragments after purification as the template, PCR was again
conducted using the M13 primer M3 and M13 primer RV as the primers
to amplify the DNA fragment of about 1 kb containing the mutant
proB gene sequence. After digestion with Eco0651 and SacII, the DNA
fragment was ligated to a DNA fragment of about 6.8 kb, as
recovered by digestion of pPRO-1 with Eco0651 and SacII and
subsequent agarose gel electrophoresis and isolation and
purification by using Prep-A-Gene DNA Purification System (Bio-Rad
Co.). Using the ligation product, the Escherichia Coli ATCC 33625
was transformed to prepare tetracycline resistant transformants.
Several of these transformants and the Escherichia Coli ATCC 33625
carrying pPRO-1 were replicated on an M9 minimal agar culture
medium with addition of 3,4-dehydroproline(100mg). All the
transformants were grown, but the Escherichia Coli ATCC 33625
carrying the pPRO-1 was not grown. It was confirmed that a plasmid
in which the proB gene of the pPRO-1 was modified into a
desensitized type was constructed. Using conventional methods,
plasmids were extracted from these transformants for restriction
analysis, which indicates that all the plasmids had the same
structure. The plasmid was defined as pKSR24.
[0087] The pKSR24 thus prepared was digested with PstI and BglII,
and was blunt ended by using a DNA blunting kit (manufactured by
Takara Brewery, Co.). By agarose gel electrophoresis and with
Prep-A-Gene DNA Purification System (Bio-Rad Co.), a DNA fragment
of about 2.9 kb containing the mutant proBA gene was isolated and
purified. A ClaI digest of pPACl as a plasmid with a
high-temperature induction type promoter and restriction sites
shown in FIG. 3 was ligated to the DNA fragment after the fragment
was blunt ended by means of a DNA blunting kit. Using the ligation
product, the Escherichia Coli ATCC 33625 was transformed, and
plasmids were extracted from the transformants to recover pKSR25
having a structure where the mutant proBA was inserted downstream
of the high-temperature induction type promoter of pPAC1 so that
the transcription direction of the mutant might be a sequential
direction.
[0088] pKSR101 prepared in Example 1 was digested with EcoRI and
BdlII, and was then blunt ended by using a DNA blunting kit, and a
DNA fragment containing the KAL gene of about 1.2 kb was isolated
and purified by using agarose gel electrophoresis and a Prep-A-Gene
DNA Purification System (manufactured by Bio-Rad Co.). The DNA
fragment of about 1.2 kb ligated with a DNA fragment recovered by
digesting pKSR25 with XhoI and blunt ending the digested product
with a DNA blunting kit. Using the ligation product, the
Escherichia coli ATCC 33625 was transformed, and ampicillin
resistant transformants were recovered from the transformants.
Several transformants were assayed for 3,4-dehydroproline
resistance and KAL activity. It was confirmed that all the
transformants had 3,4-dehydroproline resistance and KAL activity.
By conventional methods, plasmids were extracted from eight such
transformants for restriction analysis, which indicates that all
the plasmids had the same structure. The plasmids was defined as
pKSR125. The plasmid construction process and the restriction map
of pKSR125 are shown in FIG. 3.
Example 9
[0089] 4(S)HYP Production by Culturing With Addition of Glyoxylic
Acid
[0090] A mutant strain resistant to azetidine-2-carboxylic acid as
a proline analog was induced from the strain NHK46 prepared in
Example 2 as follows. The strain NHK46 cultured in the same manner
as in Example 2 was subjected to a mutagenesis in the same manner
as in Example 2, and then smeared on an M9 minimal agar culture
medium with addition of 0.5% glucose, 0.5 g/l glutamic acid, 100
.mu.g/l lipoic acid, and 100 mg/l azetidine-2-carboxylic acid, and
incubated at 37.degree. C. for 2 days. Among the resulting
colonies, larger ones were harvested, to obtain
azetidine-2-carboxylate resistant mutant strain NHK 47.
[0091] pKSR125 prepared in Example 8 was introduced into the
strains NHK46 and NHK47 to obtain transformants by using ampicillin
resistance as the marker. The individual transformants and the
strain NHK 46 carrying pKSR101 (prepared in Example 2) were
cultured in the same manner as in Example 2, and these culture
supernatants were assayed by HPLC to determine 4(S)HYP.
[0092] HPLC Assay Conditions
[0093] Column: Shiseido CapcellPak-C18 (4.6.times.150 mm)
[0094] Mobile phase: A; 10 mM sodium citrate (pH 4), B; a mixture
solution of equal volumes of A and methanol
[0095] Flow rate; 1.5 ml/min
[0096] Temperature; 50.degree. C.
[0097] Gradient Time Schedule of Mobile Phase
5 Time (min) B (vol %) 0-10 0-8 10-20 8-80 20-21 80-100 21-23 100
23-24 0
[0098] Detection: detection of fluorescence at Ex=470 mm and Em=530
nm
[0099] The results are shown in Table 5.
6TABLE 5 Host Plasmid 4(R)HYP(mM) 4(S)HYP(mM) Escherichia coli
pKSR101 0.0 0.0 NHK46 Escherichia coli pKSR125 0.0 2.1 NHK46
Escherichia coli pKSR125 0.0 10.3 NHK47
Example 10
[0100] 4(S)HYP Production by Two-step Reaction
[0101] By the transduction method with P1 phage, isocitrate
dehydrogenase deletion mutation (icd) was introduced into the
Escherichia coli ATCC 33625 from an Escherichia coli mutant strain
EB106 with deletion of isocitrate dehydrogenase deletion [supplied
from the E. coli Genetic Stock Center, Yale University, New Haven,
Conn., USA], to prepare strain NHK3. The mutant strain expressed
glutamic acid requirement because of the icd mutation.
[0102] Using pKSR25 prepared in Example 8, the Escherichia coli
ATCC 33625 and NHK3 were individually transformed to obtain
individually transformants using as the marker ampicillin
resistance. Furthermore, using plasmid pKSR50 (FIG. 4) derived from
pACYC177, carrying a 4.2-kb DNA fragment carrying the glutamate
dehydrogenase gene (gdh) of Escherichia coli interposed between the
PstI and ClaI sites, and an about 3-kb DNA fragment, carrying the
glucose-6-phosphate dehydrogenase gene (zwf), interposed between
the BamHI and SphI sites, the Escherichia coli NHK3 carrying pKSR25
(NHK3/pKSR25 strain) was transformed to obtain strain NHK3 carrying
pKSR50 and pKSR25 (NHK3/pKSR50+pKSR25) using as the marker the
resistance against ampicillin and chloramphenicol. Into a mutant
strain NHK23 of a mutation type (icd, sucA, putA, eda) of
Escherichia coli K-12 strain were also introduced pKSR50 and pKSR25
to obtain a strain NHK23/pKSR50+pKSR25.
[0103] In the same manner as in Example 2, Escherichia coli ATCC
33625, and the NHK3, ATCC33625/pKSR25, NHK3/pKSR25,
NHK3/pKSR50+pKSR25 and NHK23/pKSR50+pKSR25, all having been
prepared as described above, were similarly cultured in a T culture
medium at 30.degree. C. for 24 hours The resulting culture
supernatant containing 4(S)KHG prepared in Example 4 after
filtration and sterilization through a Millipore filter was added
to the resulting culture to a final 4(S)KHG concentration of 40 mM,
and the mixture was further cultured with agitation at 37.degree.
C. for 24 hours. 4(S)HYP in the culture broth was assayed by the
following method. To 80 .mu.l of the culture supernatant was added
a methanol solution (100 .mu.l) containing 1M borate buffer (pH
9.6; 20 .mu.l) and 6 mg/ml NBD-Cl
(7-chloro-4-nitrobenzo-2-oxa-1,3-diazole chloride) for reaction at
60.degree. C. in darkness for 20 minutes, followed by addition of
1N HCl (50 .mu.l) to the reaction solution to terminate the
reaction. The mixture was filtered through a Millipore filter, and
the filtrate was assayed by HPLC in the same manner as in Example 9
to assay 4(S)HYP. The results are shown in Table 6.
[0104] Alternatively, Corynebacterium glutamicum KY 10912 was
cultured with agitation in an LB culture medium for 16 hours. The
culture broth was then added into a sterilized TC culture medium of
5 ml and cultured with agitation at 30.degree. C. for 24 hours. The
culture supernatant carrying 4(S)KHG prepared in Example 4 after
filtration and sterilization through a Millipore filter was added
to the culture to a final 4(S)KHG concentration of 40 mM, and
further cultured with agitation at 37.degree. C. for 24 hours. The
culture supernatant was analyzed by HPLC as in Example 9 to assay
4(S)HYP. The results are shown in Table 6.
7TABLE 6 Host Plasmid 4(S)HYP(mM) E. coli ATCC33625 none 0.0 E.
coli ATCC33625 pKSR25 0.4 E. coli NHK3 none 0.0 E. coli NHK3 pKSR25
0.9 E. coli NHK3 pKSR50 + pKSR25 1.6 E. coli NHK23 pKSR50 + pKSR25
5.8 C. glutamicum KY10912 none 1.0
[0105] In accordance with the present invention,
(S)-4-hydroxy-2-ketogluta- ric acid and compounds from the
precursor (S)-4-hydroxy-2-ketoglutaric acid, for example
(2S,4S)-4-hydroxy-L-glutamic acid and (2S,4S)-4-hydroxy-L-proline,
can be produced in an industrially advantageous manner.
(2S,4S)-4-hydroxy-L-proline has biological actions including
anti-tumor cell activity [Cancer Res.48, 2483(1988)] and anti-mast
cell-activity (Japanese Unexamined Patent Publication No.
63-218621). (S)-4-hydroxy-2-ketoglutaric acid and
(2S,4S)-4-hydroxy-L-glu- tamic acid are useful as raw materials to
synthesize the proline.
[0106] Many different embodiments of the present invention may be
constructed without departing from the spirit and scope of the
invention. It should be understood that the present invention is
not limited to the specific embodiments described in this
specification. To the contrary, the present invention is intended
to cover various modifications and equivalent arrangements included
within the spirit and scope of the claims.
Sequence CWU 1
1
4 1 26 DNA Artificial Sequence Description of Artificial
Sequencesynthetic DNA 1 caaaagctta tgaaaaactg gaaaac 26 2 24 DNA
Artificial Sequence Description of Artificial Sequencesynthetic DNA
2 tttggatcct tacagcttag cgcc 24 3 22 DNA Artificial Sequence
Description of Artificial Sequencesynthetic DNA 3 gacccgtgct
aatatggaag ac 22 4 22 DNA Artificial Sequence Description of
Artificial Sequencesynthetic DNA 4 gtcttccata ttagcacggg tc 22
* * * * *